BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33522289)

  • 1. Treatment options for older unfit patients with acute myeloid leukemia.
    Tang H; Jia S; Bi L; Jia W; Gao G
    Future Oncol; 2021 Mar; 17(7):837-851. PubMed ID: 33522289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
    McMahon CM; Perl AE
    Leuk Lymphoma; 2019 Mar; 60(3):583-597. PubMed ID: 30234399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Treatment Options for Acute Myeloid Leukemia in 2019.
    Cerrano M; Itzykson R
    Curr Oncol Rep; 2019 Feb; 21(2):16. PubMed ID: 30715623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapeutic modalities for acute myeloid leukemia (AML) in older adults.
    Huang LW; Olin RL
    J Geriatr Oncol; 2017 Nov; 8(6):417-420. PubMed ID: 28835351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
    DiNardo CD; Tiong IS; Quaglieri A; MacRaild S; Loghavi S; Brown FC; Thijssen R; Pomilio G; Ivey A; Salmon JM; Glytsou C; Fleming SA; Zhang Q; Ma H; Patel KP; Kornblau SM; Xu Z; Chua CC; Chen X; Blombery P; Flensburg C; Cummings N; Aifantis I; Kantarjian H; Huang DCS; Roberts AW; Majewski IJ; Konopleva M; Wei AH
    Blood; 2020 Mar; 135(11):791-803. PubMed ID: 31932844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of FLT3 mutational analysis in acute myeloid leukemia.
    Patnaik MM
    Leuk Lymphoma; 2018 Oct; 59(10):2273-2286. PubMed ID: 29164965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acute myeloid Leukemia].
    Braess J
    Dtsch Med Wochenschr; 2016 Nov; 141(24):1748-1751. PubMed ID: 27835920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
    Bose P; Vachhani P; Cortes JE
    Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates on DNA methylation modifiers in acute myeloid leukemia.
    Contieri B; Duarte BKL; Lazarini M
    Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
    Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
    Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemtuzumab Ozogamicin in
    Schlenk RF; Paschka P; Krzykalla J; Weber D; Kapp-Schwoerer S; Gaidzik VI; Leis C; Fiedler W; Kindler T; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Greil R; Hertenstein B; Krauter J; Martens U; Nachbaur D; Abu Samra M; Girschikofsky M; Basara N; Benner A; Thol F; Heuser M; Ganser A; Döhner K; Döhner H
    J Clin Oncol; 2020 Feb; 38(6):623-632. PubMed ID: 31851556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.
    Loschi M; Sammut R; Chiche E; Cluzeau T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates on targeted therapies for acute myeloid leukaemia.
    Kayser S; Levis MJ
    Br J Haematol; 2022 Jan; 196(2):316-328. PubMed ID: 34350585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'.
    Bazinet A; Assouline S
    Expert Rev Hematol; 2021 Feb; 14(2):185-197. PubMed ID: 33430671
    [No Abstract]   [Full Text] [Related]  

  • 16. Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia.
    Paul S; DiPippo AJ; Ravandi F; Kadia TM
    Future Oncol; 2019 Dec; 15(34):3885-3894. PubMed ID: 31559849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future.
    Choi JH; Shukla M; Abdul-Hay M
    Acta Haematol; 2023; 146(6):431-457. PubMed ID: 37459852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
    Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
    Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
    Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
    Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute myeloid leukemia].
    Döhner K; Paschka P; Döhner H
    Internist (Berl); 2015 Apr; 56(4):354-63. PubMed ID: 25787321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.